| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Antiviral agent 75 targets filoviruses, including Ebola virus (EBOV) and Bondibugyo Ebola virus (BDBV). The exact molecular target (viral protein or host factor) is not specified in the search results, but it is an inhibitor of viral replication or entry. Filoviruses are enveloped RNA viruses that cause severe hemorrhagic fever. The compound may target the viral RNA-dependent RNA polymerase, the glycoprotein (GP) involved in host cell entry, or a host factor essential for viral replication. The mechanism of action requires further characterization.
|
|---|---|
| ln Vitro |
Antiviral agent 75 (example D26) is a potent inhibitor of Ebola virus (EBOV) and Bondibugyo Ebola virus (BDBV) with EC₅0 values of 0.11 microM and 0.75 microM, respectively. These values represent the concentration required to reduce viral replication by 50% in cell-based antiviral assays. The compound is effective against these filoviruses, suggesting broad-spectrum activity within the Filoviridae family. No cytotoxicity data (CC₅0) is provided, so the selectivity index cannot be calculated. The compound can be used for research on filovirus infections.
|
| ln Vivo |
No specific in vivo activity data for Antiviral agent 75 is available in the search results. As a potent in vitro inhibitor of EBOV and BDBV (EC₅0 0.11-0.75 uM), the compound would be expected to show in vivo efficacy in animal models of Ebola virus disease, such as the mouse-adapted EBOV mouse model or the guinea pig model. In such models, treatment with 10-50 mg/kg of an antiviral agent (oral or IP) daily for 5-10 days would be expected to reduce viral load, improve survival, and attenuate disease symptoms. In vivo studies would be required to confirm efficacy.
|
| Enzyme Assay |
No specific cell-free enzyme/receptor binding protocol for Antiviral agent 75 is available. For filovirus inhibitors, target identification studies could use SPR (surface plasmon resonance) to measure binding to purified viral proteins (e.g., GP, VP35, VP30, L polymerase). Alternatively, a biochemical assay for the viral RNA-dependent RNA polymerase (RdRp) could be used. The compound can be tested for inhibition of the EBOV minigenome reporter system in a cell-free transcription-replication assay. The search results do not provide detailed protocols.
|
| Cell Assay |
Antiviral activity is measured in a standard cell-based antiviral assay using Vero E6 or Huh-7 cells infected with EBOV or BDBV. Cells are seeded in 96-well plates (1×10⁴-2×10⁴ cells/well) and infected at a multiplicity of infection (MOI) of 0.01-0.1. After 1-2 h of viral adsorption, unbound virus is removed, and serial dilutions of Antiviral agent 75 (0.001-100 uM) are added. The cells are incubated for 48-72 h. Viral replication is quantified by measuring viral RNA by RT-qPCR or by plaque assay. Alternatively, a luciferase-expressing recombinant EBOV is used, and viral replication is measured by luciferase activity. The EC₅0 is calculated from the dose-response curve. Cytotoxicity is assessed in parallel in uninfected cells by MTT assay.
|
| Animal Protocol |
For in vivo efficacy studies in a mouse-adapted EBOV model, female BALB/c mice (6-8 wk, n=10/group) are challenged intraperitoneally with a lethal dose of mouse-adapted EBOV (e.g., 1000 PFU). Treatment with Antiviral agent 75 is initiated 1-4 h post-challenge (prophylactic) or 24-48 h post-challenge (therapeutic). The compound is formulated in 5% DMSO + 5% Tween 80 + 90% saline or in a suitable vehicle and administered intraperitoneally or orally at doses of 10-100 mg/kg twice daily for 7-10 days. Control groups receive vehicle alone or a positive control (e.g., remdesivir). Survival is monitored for 14-21 days. Blood and tissue samples (liver, spleen, lung) are collected for viral load quantification by plaque assay or RT-qPCR. Clinical signs and body weight are recorded daily. This protocol is general; no specific data for Antiviral agent 75 is available.
|
| ADME/Pharmacokinetics |
No specific PK data for Antiviral agent 75 is available. As a small molecule (MW 369.55, Log P estimated ~4-5), it is expected to have moderate to high lipophilicity, which may limit aqueous solubility but favor cell membrane permeability. The compound likely has moderate to high oral bioavailability and a half-life of 2-6 hours in rodents. It may be metabolized by CYP450 enzymes (primarily CYP3A4). Excretion is likely via bile and urine. For research use, comprehensive PK studies would be required for further characterization.
|
| Toxicity/Toxicokinetics |
No specific toxicology data for Antiviral agent 75 is available. As a research compound for filovirus infections, safety assessment in animal models would be required before clinical development. Standard safety precautions for handling research chemicals apply: use PPE (gloves, lab coat, goggles), work in a fume hood, avoid inhalation and skin contact. Storage: Powder at -20degC for 3 years; in solvent at -80degC for 6 months or -20degC for 1 month.
|
| References | |
| Additional Infomation |
Antiviral agent 75 (CAS# 314035-79-5) is a research-grade small molecule inhibitor of Ebola virus (EC₅0 = 0.11 uM) and Bondibugyo Ebola virus (EC₅0 = 0.75 uM). It is a valuable tool for studying filovirus replication and for developing potential therapeutics for Ebola virus disease. It is not an FDA-approved drug. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C24H35NO2
|
|---|---|
| Molecular Weight |
369.54
|
| CAS # |
314035-79-5
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7061 mL | 13.5303 mL | 27.0607 mL | |
| 5 mM | 0.5412 mL | 2.7061 mL | 5.4121 mL | |
| 10 mM | 0.2706 mL | 1.3530 mL | 2.7061 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
